Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Mylan Lab (NYSE: MYL), a leading pharmaceutical company, closed at $13.53. Goldman Sachs says, "Upgrading to Buy with $19 price target, we see a bottom in shares." MYL overall option implied volatility of 46 is above its 26-week average of 39 according to Track Data, suggesting larger price movement.
Forest Labs (NYSE: FRX), a U.S.-based pharmaceutical company, closed at $36.71. Cowen says "current pipeline is more valuable than generally perceived, and we believe FRX shares can outperform the market by 15-20% as pipeline viability improves." FRX overall option implied volatility of 44 is above its 26-week average of 37 according to Track Data, suggesting larger price movement.
Daily Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
